http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Horizon Pharma plc Receives Health Canada Approval for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Years of Age and Older
-
Horizon Pharma (HZNP) Receives USPTO Notice of Allowance for RAVICTI-Related Patent App
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid
-
Horizon Pharma (HZNP) Receives USPTO Notice of Allowance for VIMOVO-Related Patent
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
-
INVESTOR NOTICE: Goldberg Law PC Announces an Investigation of Claims against Horizon Pharma plc and Strongly Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2% w/w
-
Horizon Pharma plc to Participate in Cowen and Company 36th Annual Health Care Conference
-
Horizon Pharma plc Recognizes Rare Disease Community on the "Rarest Day of the Year"
-
Horizon Pharma plc Announces Record Fourth-Quarter and Full-Year 2015 Financial Results and Confirms Full-Year 2016 Sales and Adjusted EBITDA Guidance
-
Horizon Pharma plc Announces That Health Canada Determines RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid Is Eligible for Data Protection
-
Horizon Pharma plc to Host Fourth Quarter 2015 Conference Call and Webcast on February 29, 2016
-
Horizon Pharma plc to Participate in Three Investor Conferences in February
-
National Health Partners (HPR) Completes $510M Acquisition of Crealta Holdings
-
Horizon Pharma plc Completes Acquisition of Crealta Holdings LLC
-
Horizon Pharma plc Raises Full-Year 2016 Net Sales and Adjusted EBITDA Guidance Based on Expected Close of the Crealta Holdings LLC Acquisition
-
Horizon Pharma plc to Present at the 34th Annual J.P. Morgan Healthcare Conference
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid
-
Horizon Pharma plc to Present at the 34th Annual J.P. Morgan Healthcare Conference
-
National Health Partners (HPR) Enters ACTIMMUNE Phase 1 with Fox Chase Cancer Center
-
Horizon Pharma plc and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE(R) (interferon gamma-1b) in Combination With Nivolumab in Patients With Advanced Solid Tumors
-
Horizon Pharma (HZNP) to Acquire Crealta Holdings in $510M Cash Deal
-
Horizon Pharma plc to Acquire Crealta Holdings LLC in All Cash Acquisition
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) 2%
-
Horizon Pharma plc Receives European Commission Approval for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Months of Age and Older
-
Horizon Pharma plc Withdraws Offer to Acquire Depomed, Inc.
-
Horizon Pharma plc to Present at Two Conferences in December
-
Horizon Pharma plc Provides Update on Shareholders Meeting Related to the Proposed Acquisition of Depomed, Inc.
-
Horizon Pharma plc Selected as One of Chicago Tribune's Top Workplaces in 2015
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
-
SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims Against Horizon Pharma plc and Encourages Investors to Contact the Firm
-
Horizon Pharma plc Provides Comment on Express Scripts' Business Practices
-
Horizon Pharma plc Announces Collaboration With Alliance for Lupus Research to Study RAYOS(R) (prednisone) Delayed-Release Tablets in Systemic Lupus Erythematosus
-
Horizon Pharma plc Responds to Express Scripts Lawsuit and Recent Allegations
-
Horizon Pharma plc Announces 2016 Net Sales and Adjusted EBITDA Guidance; Reviews 2020 Long-Range Plan
-
Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance
-
Horizon Pharma plc Announces Clinical Data to Be Presented at the 2015 ACR/ARHP Annual Meeting
-
Horizon Pharma plc to Present at Three Conferences in November
-
Horizon Pharma plc to Host Investor Day on November 9, 2015
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
-
Horizon Pharma plc Extends Offer to Acquire Depomed, Inc.
-
Horizon Pharma plc Corrects Misinformation in the Marketplace
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2%
-
Horizon Pharma plc Provides Update on Relationship With Specialty Pharmacies
-
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation Of Claims Against Horizon Pharma plc And Encourages Investors To Contact The Firm
-
Horizon Pharma plc Announces Favorable Markman Ruling in RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid Patent Infringement Lawsuit
-
Horizon Pharma plc to Host Third Quarter 2015 Conference Call and Webcast on November 6, 2015
-
Horizon Pharma plc Files Definitive Proxy Statement for Extraordinary General Meeting of Horizon Pharma Shareholders
-
Horizon Pharma plc Files Preliminary Proxy Materials for Special Meetings
-
Horizon Pharma plc Chairman and Chief Executive Officer Timothy P. Walbert Inducted Into Chicago Area Entrepreneurship Hall of Fame at UIC Institute for Entrepreneurial Studies

